216 related articles for article (PubMed ID: 21200371)
1. FDA puts restrictions on use of controversial diabetes drug.
Mayo Clin Womens Healthsource; 2011 Feb; 15(2):3. PubMed ID: 21200371
[No Abstract] [Full Text] [Related]
2. FDA committee urges tight restrictions on rosiglitazone.
Roehr B
BMJ; 2010 Jul; 341():c3862. PubMed ID: 20639290
[No Abstract] [Full Text] [Related]
3. Rosiglitazone: what went wrong?
Cohen D
BMJ; 2010 Sep; 341():c4848. PubMed ID: 20819889
[No Abstract] [Full Text] [Related]
4. Commentary: What can we learn from the continuing regulatory focus on the thiazolidinediones?
Freemantle N
BMJ; 2010 Sep; 341():c4812. PubMed ID: 20819888
[No Abstract] [Full Text] [Related]
5. The rosiglitazone story--lessons from an FDA Advisory Committee meeting.
Rosen CJ
N Engl J Med; 2007 Aug; 357(9):844-6. PubMed ID: 17687124
[No Abstract] [Full Text] [Related]
6. The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience.
Hiatt WR; Kaul S; Smith RJ
N Engl J Med; 2013 Oct; 369(14):1285-7. PubMed ID: 23992603
[No Abstract] [Full Text] [Related]
7. Responding to an FDA warning--geographic variation in the use of rosiglitazone.
Shah ND; Montori VM; Krumholz HM; Tu K; Alexander GC; Jackevicius CA
N Engl J Med; 2010 Nov; 363(22):2081-4. PubMed ID: 21083379
[No Abstract] [Full Text] [Related]
8. Regulatory action on rosiglitazone by the U.S. Food and Drug Administration.
Woodcock J; Sharfstein JM; Hamburg M
N Engl J Med; 2010 Oct; 363(16):1489-91. PubMed ID: 20942663
[No Abstract] [Full Text] [Related]
9. The Avandia debate: an unhappy conclusion.
Bloomgarden Z; Handelsman Y
J Diabetes; 2010 Dec; 2(4):221-2. PubMed ID: 20923505
[No Abstract] [Full Text] [Related]
10. Rosiglitazone: failure of oversight or demons imagined?
Susman J
J Fam Pract; 2007 Sep; 56(9):696, 703. PubMed ID: 17764640
[No Abstract] [Full Text] [Related]
11. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes.
Misbin RI
Diabetes Care; 2007 Dec; 30(12):3141-4. PubMed ID: 18042753
[No Abstract] [Full Text] [Related]
12. Assessing the cardiovascular safety of diabetes therapies.
Goldfine AB
N Engl J Med; 2008 Sep; 359(11):1092-5. PubMed ID: 18784098
[No Abstract] [Full Text] [Related]
13. Why the Avandia scandal proves big pharma needs stronger ethical standards.
Philpott S; Baker R
Bioethics; 2010 Oct; 24(8):ii-iii. PubMed ID: 21050246
[No Abstract] [Full Text] [Related]
14. Licensing drugs for diabetes.
Lehman R; Yudkin JS; Krumholz H
BMJ; 2010 Sep; 341():c4805. PubMed ID: 20819887
[No Abstract] [Full Text] [Related]
15. Rosiglitazone and the FDA.
Joffe HV; Parks MH; Meyer RJ; Jenkins JK; Temple R
N Engl J Med; 2007 Oct; 357(17):1775-6; author reply 1777. PubMed ID: 17761586
[No Abstract] [Full Text] [Related]
16. Diabetes drug safety update: Avandia and your heart.
Johns Hopkins Med Lett Health After 50; 2010 Jun; 22(4):1-2, 7. PubMed ID: 20572316
[No Abstract] [Full Text] [Related]
17. Drug safety. Planned study of Avandia in doubt after FDA review.
Kean S
Science; 2010 Jul; 329(5990):375. PubMed ID: 20651123
[No Abstract] [Full Text] [Related]
18. Rosiglitazone, marketing, and medical science.
Moynihan R
BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
[No Abstract] [Full Text] [Related]
19. Outlook on diabetes drug less than rosy. Early work suggests that rosiglitazone (Avandia) may not be best for the heart.
Harv Heart Lett; 2007 Aug; 17(12):1-2. PubMed ID: 17717888
[No Abstract] [Full Text] [Related]
20. Diabetes recall. Though Rezulin's withdrawal is a blow for some patients, there are ways to cope. Here's how.
Gorman C
Time; 2000 Apr; 155(13):94. PubMed ID: 11009709
[No Abstract] [Full Text] [Related]
[Next] [New Search]